论文部分内容阅读
1990年7月至12月,我们对收治的72例食管癌病人进行了超分割放疗与常规放疗的前瞻性随机临床研究。病人随机对照分组为常规放疗组(A 组)与超分割放疗组(B 组),两组病人临床情况基本相似。所有病例随访均超过一年。一年生存率分别为 A 组50%,B 组为77.8%,经统计学处理,B 组和 A 组 P<0.005,差异有显著意义。结果表明:超分割放射治疗食管癌作为一种新的治疗方法可提高食管癌的近期疗效及生存率。
From July to December 1990, we conducted a prospective randomized clinical study of 72 cases of esophageal cancer patients undergoing hyperfractionated radiotherapy and conventional radiotherapy. Patients were randomized and divided into the conventional radiotherapy group (group A) and the hyperfractionated radiotherapy group (group B). The clinical conditions of the two groups of patients were basically similar. All cases were followed for more than one year. The one-year survival rate was 50% in group A and 77.8% in group B. After statistical analysis, group B and group A had a P<0.005. The difference was significant. The results showed that hyperfractionated radiotherapy for esophageal cancer as a new treatment can improve the short-term efficacy and survival of esophageal cancer.